3,4,5-三氟-2-(4-碘-2-甲基苯胺基)苯甲酸 | 212628-44-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4,5-三氟-2-(4-碘-2-甲基苯胺基)苯甲酸
• 英文名称: 3,4,5-Trifluoro-2-(4-iodo-2-methyl-phenylamino)-benzoic acid
• 英文别名: 2-(4-iodo-2-methyl-phenylamino)-3,4,5-trifluoro-benzoic acid；2-(2-Methyl-4-iodophenylamino)-3,4,5-trifluorobenzoic acid；2-(4-Iodo-2-methylphenylamino)-3,4,5-trifluorobenzoic acid；3,4,5-trifluoro-2-(4-iodo-2-methylanilino)benzoic acid
• CAS: 212628-44-9
• 化学式: C₁₄H₉F₃INO₂
• 分子量: 407.131
• InChiKey: IKYHHUKKYADHCL-UHFFFAOYSA-N

物化性质

• 沸点：
  392.5±42.0 °C(Predicted)
• 密度：
  1.859±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,4,5-三氟-2-(4-碘-2-甲基苯胺基)苯甲酸 、 O-环丙基甲基羟胺盐酸盐 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 以61%的产率得到N-(环丙基甲氧基)-3,4,5-三氟-2-[(4-碘-2-甲基苯基)氨基]苯甲酰胺
  参考文献：
  名称：

  The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901

  摘要：

  A novel series of benzhydroxamate esters derived from their precursor anthranilic acids have been prepared and have been identified as potent MEK inhibitors. 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide, CI-1040, was the first MEK inhibitor to demonstrate in vivo activity in preclinical animal models and subsequently became the first MEK inhibitor to enter clinical trial. CI-1040 suffered however from poor exposure due to its poor solubility and rapid clearance, and as a result, development of the compound was terminated. Optimization of the diphenylamine core and modi. cation of the hydroxamate side chain for cell potency, solubility, and exposure with oral delivery resulted in the discovery of the clinical candidate N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide PD 0325901. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.054
• 作为产物：
  描述：

  2,3,4,5-四氟苯甲酸 、 4-碘-2-甲基苯胺 生成 3,4,5-三氟-2-(4-碘-2-甲基苯胺基)苯甲酸
  参考文献：
  名称：

  The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901

  摘要：

  A novel series of benzhydroxamate esters derived from their precursor anthranilic acids have been prepared and have been identified as potent MEK inhibitors. 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide, CI-1040, was the first MEK inhibitor to demonstrate in vivo activity in preclinical animal models and subsequently became the first MEK inhibitor to enter clinical trial. CI-1040 suffered however from poor exposure due to its poor solubility and rapid clearance, and as a result, development of the compound was terminated. Optimization of the diphenylamine core and modi. cation of the hydroxamate side chain for cell potency, solubility, and exposure with oral delivery resulted in the discovery of the clinical candidate N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)benzamide PD 0325901. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.10.054

文献信息

• Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
  申请人：——

  公开号：US20040054172A1

  公开（公告）日：2004-03-18

  The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystaline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

  本发明涉及氧化酯化的4-碘苯胺基苯基羟肟酸衍生物，以及其药物组合物和使用方法。本发明还涉及氧化酯化的4-碘苯胺基苯基羟肟酸衍生物的晶体形式，药物组合物和使用方法。
• Combination chemotherapy
  申请人：——

  公开号：US20040171632A1

  公开（公告）日：2004-09-02

  Mitotic inhibitors such as paclitaxel have improved antitumor activity when used in combination with a selective MEK inhibitor, especially a phenyl amine compound of Formula I and II: 1

  有丝分裂抑制剂如紫杉醇在与选择性MEK抑制剂结合使用时，特别是Formula I和II的苯胺化合物，已提高抗肿瘤活性。
• Process for making n-aryl-anthranilic acids and their derivatives
  申请人：——

  公开号：US20040039208A1

  公开（公告）日：2004-02-26

  The present invention relates to a process for the preparation of N-arylanthranilic acids, and a process for the preparation of N-aryl anthranilic esters, amides, and hydroxamic esters.

  本发明涉及一种制备N-芳基蒽酰胺酸的方法，以及制备N-芳基蒽酰酯、酰胺和羟肟酯的方法。
• 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
  申请人：——

  公开号：US20020022647A1

  公开（公告）日：2002-02-21

  Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula 1 where R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are hydrogen or substituent groups such as alkyl, and where R 7 is hydrogen or an organic radical, and Z is COOR 7 , tetrazolyl, CONR 6 R 7 , or CH 2 OR 7 , are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.

  苯基氨基苯甲酸，苯甲酰胺和苄醇衍生物的公式1，其中R1、R2、R3、R4、R5和R6为氢或取代基团，如烷基，其中R7为氢或有机基团，Z为COOR7、四唑基、CONR6R7或CH2OR7，是MEK的有效抑制剂，因此可用于治疗癌症和其他增殖性疾病，如炎症、银屑病和再狭窄，以及中风、心力衰竭和免疫缺陷病。
• Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
  申请人：Barrett Douglas Stephen

  公开号：US20050176820A1

  公开（公告）日：2005-08-11

  The present invention relates to oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof. The present invention also relates to crystalline forms of oxygenated esters of 4-iodophenylamino benzhydroxamic acid derivatives, pharmaceutical compositions and methods of use thereof.

  本发明涉及4-碘苯胺苯羟肟酸衍生物的含氧酯、制药组合物及其使用方法。本发明还涉及含氧酯的晶体形式、制药组合物及其使用方法。